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ABSTRACT
Objectives: There is a lack of evidence regarding the
effectiveness of graphic health warning labels (GHWL)
in different individuals, including patients with chronic
obstructive pulmonary disease (COPD). Investigating
knowledge and attitudes may allow better
implementation of future public health policies. We
hypothesised that differences in the impact of GHWL
exist between non-smokers, smokers and patients with
COPD, with decreased efficacy in those groups who are
longer and more frequently exposed to them.
Participants and setting: 163 participants (54%
male, aged 21–80) including 60 non-smokers, 53
smokers and 50 patients with COPD (Gold stage II–IV),
attending London respiratory outpatient clinics,
participated in case-controlled surveys (50 items).
Outcome measures: Ten different GHWL were shown
and demographics, smoking history, plans to quit,
smoking-risk awareness, emotional response,
processing and impact of GHWL on behaviour were
recorded. Patients were further asked to prioritise the
hypothetical treatment or prevention of five specific
smoking-related diseases.
Results: Smokers, in particular those with COPD, were
less susceptible to GHWL than non-smokers; 53.4% of
all participants expressed fear when looking at GHWL,
non-smokers (71.9%) more so than smokers (39.8%,
p<0.001). COPD participants were less aware of the
consequences than non-COPD participants (p<0.001),
including an awareness of lung cancer (p=0.001). Lung
cancer (95%), oral cancer (90.2%), heart disease
(84.7%) and stroke (71.2%) were correctly associated
with smoking, whereas blindness was least associated
(23.9%). However, blindness was prioritised over oral
cancer, stroke and in patients with COPD also over heart
disease when participants were asked about
hypothetical treatment or prevention.
Conclusions: GHWL are most effective in non-
smokers and a desensitisation effect was observed in
smokers and patients with COPD. As a consequence, a
tailored and concerted public health approach to use
such messages is required and ‘blindness’ deserves
to be mentioned in this context because of an
unexpectedly high-deterring impact.
INTRODUCTION
Tobacco use is one of four factors respon-
sible for the majority of all worldwide deaths
caused by non-communicable disease,
according to the WHO.1 It causes lung
cancer and chronic obstructive pulmonary
disease (COPD).2 3 Smoking cessation at any
stage improves health outcomes, even in
patients with advanced COPD4 and, although
it is difﬁcult to change smoking behaviour,
public health campaigns featuring primary
and secondary prevention inﬂuence smoking
habits and public health in the long term.5
Graphic health warning labels (GHWL)
have been used over several years to promote
smoking cessation and increase awareness of
smoking-related side effects.6 Various studies
Strengths and limitations of this study
▪ Detailed assessments used structured surveys,
which were designed following an internal peer-
review process among three tertiary teaching
hospitals and one academic institution.
▪ Patients with chronic obstructive pulmonary
disease (COPD) were more reluctant to take part
in the research and a more substantial aversion
to graphic health warning labels may have been
masked in this group. Further, the COPD cohort
was older and had more male participants than
the other groups.
▪ Data were collected directly from patient groups
in an outpatient setting, and therefore generalis-
ability to the wider population may be limited.
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have described their efﬁcacy, which appears to be more
effective than text-only labels,7–11 but difﬁculties still
persist to encourage smoking cessation.12 Despite all
efforts and a comprehensive government tobacco plan
(box 1),13 more than 21% of the UK population con-
tinue to smoke.14
Awareness of smoking-related ill health
Knowledge of smoking-related diseases among smokers
and non-smokers, including exposure to second-hand
smoke, oral health and various types of cancer, differs
signiﬁcantly,10 15 even among medical students.16 While
cardiovascular and respiratory risks are well acknowl-
edged, this is not true for other diseases, particularly for
blindness.17–21
COPD and GHWL
Vardavas et al8 investigated the signiﬁcant role GHWL
might play in preventing smoking during early adoles-
cence, a crucial period in which experimentation and
addiction commonly occur.22 Despite their efﬁcacy, long-
term exposure to such warnings may have a desensitising
effect on attitudes towards smoking cessation.
Desensitisation to GHWL could have the greatest
impact in patients with COPD because they are exposed
long-term to the efforts of public health campaigns.
Indeed, older smokers are also reported to demonstrate
less interest in quitting smoking23 and they more often
attribute symptoms to the effect of ageing or a non-
medical cause.24 A reduced respiratory symptom attribu-
tion to smoking would lead to a reduced likelihood to
quit.25 COPD is also associated with a higher prevalence
of depression, poor memory, decreased attention26 and
mild cognitive impairment.27 28 These factors may
reduce the cognitive impact GHWL have on smoking
cessation and warrant further investigation.
The present study aims to investigate differences in
GHWL impact, and knowledge of smoking outcomes in
smokers, non-smokers and patients with COPD; we
hypothesised a decreased efﬁcacy on individuals with
increased exposure to smoking. Identifying individual
responses may facilitate a more tailored public health
approach for the utilisation of GHWL in future health
policies.
PATIENTS AND METHODS
The study was approved by the local research ethics com-
mittee (reference number 12/NE/0013) and was per-
formed at Guy’s & St Thomas’ NHS Foundation Trust,
London, UK. Prior to participation, informed and
written consent was obtained for all participants.
Inclusion criteria were: ﬂuent English, respiratory depart-
ment outpatients, age 21–80 years, both genders,
smokers, non-smokers and ex-smokers, as well as patients
with COPD (GOLD stage II–IV) with a prediagnosed con-
dition. Patients who were unable to communicate, under-
stand or view the GHWL or consent form were excluded.
One hundred and sixty-three participants were
studied, including 60 non-smokers, 53 smokers and 50
patients with COPD (smokers and non-smokers, see
online supplementary tables E1 and E2). A structured
survey was designed to investigate the awareness of
smoking risks and the effectiveness of GHWL within
these groups.
Structured survey
The survey contained 50 items based on those utilised
by previous studies.19 20 29 These items were included
following an internal peer review process among three
tertiary teaching hospitals and one academic institution
(King’s College London, UK; the survey is available in
the appendix and more details can be found in the
online supplementary materials). The following health
risks were included:
1. Mouth and throat cancer
Smoking cessation causes a 50% reduction in the risk
of oral cancer within 5 years.30
2. Lung cancer
Approximately 90% of male lung cancer deaths and
75–80% of female lung cancer deaths in the USA are
caused by smoking each year.31
3. Heart disease
Estimations attribute 40% of heart disease to
smoking.32
4. Stroke
Smoking could increase the risk of stroke by 2–
4-fold.33
5. Blindness
Estimations attribute smoking to approximately 20%
of new blindness in people over the age of 50.34
Participants were then shown GHWL (n=10) and their
responses were recorded. More details about this can be
found in the online supplementary material. The
surveys were conducted by investigators with a medical
background who were instructed to remain neutral and
not to inﬂuence decision-making. Training took place
prior to data collection and at two weekly intervals,
lasting 15–20 min, to standardise the interview process
and minimise investigator-led bias.
Statistical analysis
Sample size calculations revealed that at least 50 partici-
pants were required in each arm of the study to achieve a
Box 1 Government tobacco plan13
The six-part governmental tobacco control plan for England
1. Stopping promotion of tobacco
2. Making tobacco less affordable
3. Effective regulation of tobacco products
4. Helping tobacco users to quit
5. Reducing exposure to second-hand smoke
6. Effective communications for tobacco control
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power of 0.8 (for more details on the sample size calcula-
tion, please refer to the online supplementary materials).
Data were collected using MS Excel 2007 (Microsoft
Corporation, Seattle, Washington, USA); they were ana-
lysed using SPSS statistics 21 (IBM, New York, New York,
USA) and tested for a normal distribution using the
Kolmogorov-Smirnov test. χ2 tests were used to compare
categorical data. Non-categorical data were analysed
using unpaired t tests, if data were normally distributed,
or Mann-Whitney non-parametric tests if they were non-
normally distributed. A regression analysis was con-
ducted, using binary logistic regression and multiple
linear regression, and applied to the primary outcome
measure of knowledge score (the number of
smoking-related risks that each participant was aware of).
The independent variables in the analysis were age,
gender, sex, ethnicity, smoking status and COPD status.
Data are presented as mean (SD), unless otherwise indi-
cated. A level of signiﬁcance was deﬁned as p<0.05.
RESULTS
A total of 163 participants (54% male (m), age 52.4
(17.8) years) were included, with 60 non-smokers
without airway disease (38.3% m; age 41.4 (16.4) years),
53 smokers without airway disease (69.8% m, age 49.7
(13.1) years) and 50 patients with COPD (56% m; age
68.6 (10.7) years); this group contained smokers and
non-smokers (please refer to the online supplementary
tables E1 and E2). The group with non-smokers had
more female participants than the group with smokers
and the one with patients with COPD. The COPD group
was older than the other two groups. The ethnic back-
ground of all participants was predominantly ‘White’
(79%), followed by ‘Asian/Asian British’ (10%) and
‘Black/Black British’ (9%; table 1).
AWARENESS OF HEALTH RISKS ASSOCIATED WITH
SMOKING
In total, 93.3% of smokers without COPD stated that
they had thought about the health risks associated with
smoking compared with 75% of smokers with COPD
(p=0.097). Across all participants, the greatest awareness
was of lung cancer (95.0%), followed by mouth and
throat cancer (90.2%), heart disease (84.7%) and stroke
(71.2%). Blindness was least well known (23.9%).
Non-smokers revealed an increased awareness of asso-
ciations between smoking and mouth and throat cancer
(p=0.004) compared with smokers (ﬁgure 1). Patients
with COPD expressed a decreased awareness of lung
cancer (p=0.001), heart disease (p=0.012), stroke
(p=0.001) and mouth and throat cancer (p<0.001) com-
pared with the other groups (ﬁgure 2). There was no
signiﬁcant difference between groups in the awareness
of blindness.
Impact of smoking consequences on future behaviour
Smokers were more motivated to quit smoking if, hypo-
thetically, they were to develop heart disease (89.7% vs
75%, p<0.001), stroke (82.8% vs 75%, p<0.001), blind-
ness (89.7% vs 66.7%, p<0.001), mouth and throat
cancer (93.1% vs 75%, p<0.001) or lung cancer (89.7%
vs 83.3%, p<0.001) when compared to patients with
COPD. Non-smokers scored similarly to patients with
COPD (9.4 (1.1) vs 8.7 (2.3) points, p=0.055) when asked
about the harmfulness of smoking to health, but they scored
higher than current smokers (8.4 (1.5) points, p=0.004;
table 2).
When given the choice to avoid one of ﬁve hypothetical
conditions associated with smoking, smokers rated lung
cancer highest, followed by heart disease, blindness,
mouth and throat cancer and ﬁnally stroke. Similarly,
non-smokers ranked lung cancer highest, followed by
heart disease, blindness, mouth and throat cancer and
stroke. Patients with COPD ranked lung cancer highest,
followed by blindness, heart disease, mouth and throat
cancer and stroke. However, no signiﬁcant differences
existed between ranks in the different subgroups (table 3
and see online supplementary table E3).
When participants had to choose to hypothetically
treat only one of these ﬁve smoking-associated condi-
tions, smokers most commonly ranked lung cancer ﬁrst,
Table 1 Participants’ demographics, revealing mean age (with range), number of participants according to gender (%) and
ethnicity (%) for all groups
All (N=163)
Non-smokers
(non-COPD;N=60)
Smokers
(non-COPD; N=53) COPD (N=50)
χ2/one-way
ANOVA (p value)
Age in years (range) 52.4 (18–90) 41.4 (18–85) 49.7 (24–74) 68.6 (40–90) <0.001
Sex (N, %)
Male 88 (54%) 23 (38%) 37 (70%) 28 (56%) 0.003
Female 75 (46%) 37 (62%) 16 (30%) 22 (44%)
Ethnicity/N
White 129 (79%) 43 (72%) 41 (77%) 45 (90%)
Asian/Asian British 17 (10%) 9 (15%) 7 (13%) 1 (2%) 0.074
Black/Black British 14 (9%) 5 (8%) 5 (9%) 4 (8%)
Mixed 3 (2%) 3 (5%) 0 (0%) 0 (0%)
ANOVA, analysis of variance; COPD, chronic obstructive pulmonary disease.
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followed by heart disease, blindness, stroke and lastly
mouth and throat cancer. Non-smokers most commonly
ranked lung cancer highest, followed by heart disease,
blindness, mouth and throat cancer and stroke. Patients
with COPD most commonly ranked lung cancer highest,
followed by blindness, heart disease, mouth and throat
cancer and stroke. Smokers were signiﬁcantly more likely
to seek hypothetical treatment for lung cancer compared
with non-smokers (p=0.005) who were more likely to seek
treatment for mouth and throat cancer (p=0.043; table 3
and see online supplementary table E4).
Response and processing of GHWL
Among all participants, 53.4% of patients experienced
fear after viewing pictures of GHWL, 78.5% of partici-
pants expressed disgust and 28.8% would actively avoid
labels if they saw them in public. Smokers experienced
less fear when looking at GHWL (71.9%) compared
with non-smokers (39.8%; p<0.001; ﬁgure 3). There was
no signiﬁcant difference in avoiding GHWL or feelings
of disgust between smokers and non-smokers (table 3).
Patients with COPD experienced less fear, disgust and
were less likely to avoid looking at GHWL compared
with other groups (p=0.016; ﬁgure 4), but only avoid-
ance reached the level of statistical signiﬁcance
(table 4).
GHWL would have been more sufﬁcient to prevent or
stop smoking in non-smokers than smokers (p<0.001).
Non-smokers were more likely than smokers to think
about the warning messages on cigarette packaging
(p=0.006) and talk about the warning labels to others
(p<0.001; online supplementary ﬁgure E1). Patients with
COPD read the packaging less often (p<0.001) and less
carefully (p=0.010); they were less likely to think about
Figure 1 Awareness of
smoking-related consequences
(smokers vs non-smokers),
showing the differences in
number of respondents (%).
Significant differences are marked
(**p<0.01).
Figure 2 Awareness of
smoking-related consequences
(chronic obstructive pulmonary
disease (COPD) vs non-COPD),
showing the differences in
number of respondents (%).
Significant differences are marked
(*p<0.05; **p<0.01; ***p<0.001).
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the messages (p=0.001), talk to others about warning
labels (p<0.001), think about warning labels when they
were not in sight (p<0.023) or were less likely to keep a
warning label at home as a reminder (p=0.013; online
supplementary ﬁgure E2). No signiﬁcant differences
existed between COPD and non-COPD groups when
comparing whether the warning labels were sufﬁcient
motivation to stop smoking (p=0.240; table 4).
In terms of the age and sex of participants, females
were more likely to experience fear when compared with
males (p=0.002), but not disgust or active avoidance of
labels. They were also more likely to stop smoking follow-
ing exposure (p=0.002) and more likely to think about
GHWL messages when they were not in sight (p=0.023).
Those who experienced fear were younger (p=0.037), as
were those who would actively avoid looking at labels
(p=0.008; table 5). Increased age was signiﬁcantly corre-
lated with a decrease in depth of processing of labels (r=
−0.386, p<0.001); older participants exhibited a
decreased level of attention to detail when reading
GHWL (r=−0.315, p<0.001); they paid less attention to
them (r=−0.351, p<0.001); they were thinking less often
about the labels (r=−0.375, p<0.001), even when GHWL
were not in sight (r=−0.201, p<0.010), and they talked
less about them (r=−0.31, p<0.001; table 6).
The regression analysis to understand whether there
were independent predictors of knowledge or awareness
of smoking-related consequences revealed no signiﬁcant
association with the overall knowledge score of the
respondent’s age (p=0.333), gender (p=0.079), race
(p=0.552) or smoking status (p=0.756).
DISCUSSION
Patients with COPD exhibit a decreased response to
GHWL, an effect that can be referred to as desensitisa-
tion, whereas non-smokers and smokers without airway
disease responded better. The use of GHWL evoked an
emotional response of fear and disgust in the majority of
participants, particularly in non-smokers, in females and
in younger participants.
Table 2 Awareness of smoking consequences
COPD
(n=50)
Non-COPD
(n=113) p Value
Smokers
(n=99)
Non-smokers
(n=64) p Value
(1) How harmful is smoking to health? (non-normal)
mean (SD)
8.7 (2.3) 8.9 (1.4) 0.564 8.4 (1.5) 9.4 (1.1) 0.004
Awareness of smoking-related side effects: total score
out of 5, mean (SD)
3.1 (1.4) 3.9 (1.0) <0.001 3.6 (1.2) 3.8 (1.1) 0.293
Awareness of heart disease as related to smoking (%) 74.0 89.4 0.012 85.9 82.8 0.598
Awareness of stroke as related to smoking (%) 54.0 78.8 0.001 69.7 73.4 0.607
Awareness of blindness as related to smoking (%) 18.0 26.5 0.238 23.2 25.0 0.796
Awareness of mouth and throat cancer as related to
smoking (%)
72.0 98.2 <0.001 84.8 98.4 0.004
Awareness of lung cancer as related to smoking (%) 88.0 99.1 0.001 93.9 98.4 0.167
Item 1 showing each group’s response (1–10) of the perceived harmfulness of smoking to health (mean (SD)), number of known
smoking-related consequences from 1–5 (mean (SD)) and total number (%) in each group that was aware of the smoking consequence.
Statistically significant results are highlighted in grey.
COPD, chronic obstructive pulmonary disease.
Table 3 Showing the number (%) of each group that would hypothetically prevent or treat the named condition if they could
choose only one from the given list
COPD
(n=50)
Non-COPD
(n=113)
p
Value
Smokers
(n=99)
Non-smokers
(n=64) p Value
If you could prevent or treat only one of heart disease,
stroke, blindness, mouth and throat cancer and lung
cancer, which would you choose? (% choosing each
option)
(Rank
1–5)
(Overall
rank 1–5)
Heart disease (%) 16.0 (3) 24.8 (2) 0.078 19.7 (2) 25.8 (2) 0.196 (2)
Stroke (%) 6.0 (5) 7.5 (5) 0.621 6.6 (5) 7.8 (5) 0.668 (5)
Blindness (%) 19.0 (2) 17.3 (3) 0.704 16.7 (3) 19.5 (3) 0.509 (3)
Mouth and throat cancer (%) 9.0 (4) 8.4 (4) 0.860 6.6 (5) 11.7 (4) 0.105 (4)
Lung cancer (%) 50.0 (1) 40.3 (1) 0.102 49.5 (1) 33.6 (1) 0.005 (1)
Ranks of each condition (1–5) are stated in columns 1, 2, 4 and 5 with the overall rank (1–5) in column 6. The table is a composite score of
online supplementary table E3 (if you can prevent only one named disease) and supplementary table E4 (if you could treat only one named
disease) which are available in the online supplementary materials. Statistically significant results are highlighted in grey.
COPD, chronic obstructive pulmonary disease.
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The effect of desensitisation can be deﬁned as a
process where repeated exposure results in habituation
of a cognitive, emotional and physiological response.
Psychological research has shown that novel events are
processed more extensively than common events,35 36
and although some papers discuss desensitisation as a
possible mechanism for a decreased impact of
GHWL,37 38 it has largely been described in relation to
graphic video game imagery and violence.39
Awareness of smoking consequences and impact on future
behaviour
Various studies have outlined an increased awareness of
smoking-related respiratory complications in patients
with COPD.29 34 40–43 In contrast, our study found that
patients with COPD had a decreased awareness of
consequences compared with patients without COPD
and were less likely to quit if they developed any of the
diseases; the same was true when smokers were com-
pared with non-smokers. Smokers also scored signiﬁ-
cantly lower than non-smokers when asked how harmful
smoking was to their health and they had a decreased
awareness of mouth and throat cancer.
The awareness of ‘blindness’ and its role in public health
campaigns
Blindness was the least well-known smoking-related risk
despite all participants being highly motivated to
prevent and treat it (ranked 2nd or 3rd in all groups,
following lung cancer and heart disease). Up to 20% of
new onset blindness in patients are attributed to
smoking44 and previous studies have found it more
motivational than conventional messages in smoking
prevention.18–20
Smoking-related lung cancer, heart disease, mouth
and throat cancer and stroke are well recognised and
publicised in printed media and TV advertising.34 45
This awareness is reﬂected across all study groups.
However, it has been established that current smokers
have a lower understanding of other risks including
macular degeneration, cataracts and oral diseases com-
pared with non-smokers.17 18 21 In one study, less than
10% of patients older than 18 years were able to associ-
ate blindness with smoking.34
A study from Australia has shown an increased aware-
ness of smoking-related eye disease due to public health
strategies,46 and an increased emphasis on blindness in
this context could have the potential to motivate and
encourage smoking cessation.18
Future implications
GHWL appear to lose efﬁcacy with increased exposure.
Unfortunately, this limits the extensive use for the primary
target groups, in particular long-term smokers and
patients with COPD. A balance between the use of GHWL
and the observed desensitisation effects needs to be con-
sidered. Therefore, speciﬁc health messages should be tar-
geted at these cohorts over deﬁned periods and
reorganised with regular campaigns to avoid desensitisa-
tion. The knowledge that less well-known risks (eg, blind-
ness) could have a similar impact as more well-known risks
of smoking (eg, lung cancer and heart disease) provides
the chance to alternate features of different diseases on
GHWL in concerted public health campaigns.
Indeed, different approaches to promote smoking ces-
sation are still required. Over the past few years it has
been considered whether plain packages should be intro-
duced, preventing the use of illusory packaging techni-
ques as a means of attracting consumers.47 Evidence
around plain packaging is currently based on indirect
studies,48–52 and while Australia is the ﬁrst country to sell
tobacco products adopting this policy,53 54 the UK gov-
ernment, following consideration of such an approach,13
has currently rejected a proposal.
Figure 3 Emotional response to graphic health warning
labels (GHWL; smokers vs non-smokers), showing the
difference in respondents (%) experiencing fear, disgust and
avoidance after GHWL exposure. Statistically significant
differences are marked (***p<0.001).
Figure 4 Emotional response to GHWL (COPD vs
non-COPD), showing the difference in respondents (%)
experiencing fear, disgust and avoidance after GHWL
exposure. Statistically significant differences are marked
(*p<0.05; COPD, chronic obstructive pulmonary disease;
GHWL, graphic health warning labels).
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Limitations
The respondents in this study came from a hospital
setting in respiratory and outpatient departments, and
therefore a selection bias might have inﬂuenced some
of the outcomes of our survey; the generalisability of our
data should therefore be considered with caution.
Several GHWL were shown to participants within a short
time period and this could have caused a greater emo-
tional response than showing single pictures.
Further, the COPD cohort tended to be older, with
more male participants, whereas the non-smoker group
consisted of proportionally more females. The numbers
used in the analysis however, were taken from a reason-
ably large data set and represent consistent results
among all groups, in line with previous ﬁndings. The
smoking history was variable between patients in the
COPD group as it included current smokers and also
non-smokers. This could have impacted on and limited
our results with regard to the COPD group (see online
supplementary table E1).
Patients with COPD were more reluctant to take part in
this survey and it is likely that a true aversion to GHWL
might have been underestimated. In addition, although
Hammond et al11 demonstrated that smoking cessation
was related to high-cognitive processing of labels, inten-
tion to quit smoking was investigated here rather than
actual behaviour change. Future research may need to
investigate the achieved rate of smoking cessation follow-
ing GHWL exposure and also the link between intention
and actual change of smoking behaviour.
Table 4 Emotional response and processing of GHWL, indicating the number of participants (%) who responded with fear,
disgust and avoidance and the number (%) who were motivated to stop smoking
Initial response to GHWL
COPD
(n=50)
Non-COPD
(n=113) p Value
Smokers
(n=103)
Non-smokers
(n=60) p Value
…Fear? (%) 48.0 55.8 0.360 39.8 71.9 <0.001
…Disgust? (%) 76.0 79.6 0.601 72.8 82.8 0.284
Ever avoided looking at GHWL? (%) 16.0 34.5 0.016 27.2 29.7 0.846
Are the warning labels sufficient motivation for
you to stop smoking (if a current smoker) or not
start smoking (if a non-smoker or ex-smoker)? (%)
44.0 54.0 0.240 35.4 75.0 <0.001
Processing of GHWL
Packaging processing response (1=never, 5=very often)
(1) How carefully have you ever read the
warning messages on cigarette packaging?
1.9 (1.1) 2.4 (1.3) 0.010 2.4 (1.4) 2.1 (1.1) 0.493
(2) How often do you read the warning
messages on cigarette packaging?
1.6 (1.0) 2.5 (1.3) <0.001 2.5 (1.5) 2.1 (1.1) 0.064
(3) How often have you thought about the
warning messages on cigarette packaging?
1.9 (1.3) 2.7 (1.3) 0.001 2.2 (1.2) 2.8 (1.5) 0.006
General processing response (1=never, 5=very often)
(4) Have you ever talked to others about the
warning labels on cigarette packaging?
1.5 (1.1) 2.5 (1.4) <0.001 1.8 (1.1) 2.7 (1.5) <0.001
(5) How often have you thought about the
warning messages on cigarette packages
when there has been no pack in sight?
1.5 (0.9) 1.9 (1.2) 0.023 1.6 (1.0) 2.0 (1.3) 0.112
(6) How often have you kept a warning label
from a cigarette pack?
1.0 (0.3) 1.4 (1.0) 0.013 1.2 (0.8) 1.3 (0.8) 0.995
Also, the mean (SD) processing of GHWL (1–5) over two items (packaging and general processing response). Statistically significant values
are highlighted in grey.
COPD, chronic obstructive pulmonary disease; GHWL, graphic health warning label.
Table 5 Age and gender differences in the response to graphic health warning labels (GHWL), showing differences in
gender (total number) and age (mean (SD)) in the emotional response to GHWL and motivation to stop smoking
Emotional response
to warning labels Male—yes Female—yes χ2
Mean age
of those
who said ‘yes’
Mean age
of those
who said ‘no’
t Test
(two-tailed)
Fear 37/88 50/75 0.002 50.0 (18.3) 55.6 (16.7) 0.044
Disgust 66/88 62/75 0.235 51.3 (17.4) 57.1 (18.7) 0.112
Avoidance 21/88 26/75 0.129 47.0 (16.1) 54.8 (18.0) 0.008
Sufficient to stop from smoking 35/88 48/75 0.002 51.5 (18.4) 53.9 (16.9) 0.381
Statistically significant values are highlighted in grey.
Ratneswaran C, Chisnall B, Drakatos P, et al. BMJ Open 2014;4:e004782. doi:10.1136/bmjopen-2013-004782 7
Open Access
Desensitisation is one explanation for our ﬁndings;
however, it is possible that patients with COPD demon-
strate an ambivalence towards risks to support their own
self-esteem.55 This would reduce anxiety associated with
a fear of the consequences of smoking56 and portray
itself as a ‘don’t care’ attitude. Leventhal57 postulated
that fear messages may lead to two competing processes,
either a ‘danger control’ or, in the case of our COPD
cohort, a ‘fear control’ response. Indeed, where fear-
based approaches have been used to reduce illicit drug
rates, increased rates of drug abuse were described post-
intervention.58 Further qualitative work will help under-
stand these speciﬁc responses better.
CONCLUSION
Prolonged exposure to GHWL may cause desensitisa-
tion, in particular to patients with COPD and current
smokers. To maintain their efﬁcacy, other strategies
using the intermittent application of different features
need to be employed within concerted health cam-
paigns. Blindness has to be mentioned as a speciﬁc
factor because it leads to a strong emotional response in
the context of GHWL.
The evidence provided by our research is required to
continue to develop successful public health campaigns,
in particular because plain packaging has currently been
rejected as a public health policy in the UK. These cam-
paigns should focus on improving the lack of awareness
of smoking-related diseases, especially in those with
chronic smoking behaviour. Further, the timing of
exposure to speciﬁc GHWL messages needs to be con-
sidered to avoid desensitisation. Future qualitative
research is required to explore thoughts and beliefs of
chronic smokers and patients with COPD, to understand
any ambivalence towards smoking consequences and to
investigate the underlying reasons. A more tailored
approach will help to support effective primary and sec-
ondary prevention and smoking cessation interventions.
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Breakdown of package (P) processing response
Paid close attention Thought about labels Carefully read
Age (r) −0.351 −0.375 −0.315
p Value <0.001 <0.001 <0.001
Mean score —male 2.2 (1.3) 2.3 (1.3) 2.2 (1.3)
Mean score —female 2.3 (1.3) 2.6 (1.4) 2.2 (1.2)
Gender t test p value
(two tailed)
0.915 0.312 0.788
Breakdown of general (G) processing response
Thought about when not in sight Kept a label as a reminder Talked to others about labels
Age (r) −0.201 −0.094 −0.31
p Value 0.010 0.232 <0.001
Mean score—male 1.6 (1.0) 1.3 (0.9) 2.1 (1.3)
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The overall processing is shown in the third column. Statistically significant values are highlighted in grey.
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